Edition:
United Kingdom

Shire PLC (SHPG.OQ)

SHPG.OQ on NASDAQ Stock Exchange Global Select Market

175.01USD
19 Oct 2018
Change (% chg)

$-1.97 (-1.11%)
Prev Close
$176.98
Open
$176.69
Day's High
$177.73
Day's Low
$174.91
Volume
331,316
Avg. Vol
278,723
52-wk High
$182.36
52-wk Low
$123.73

Select another date:

Fri, Oct 19 2018

Photo

Shire's drug for rare swelling disorder wins European panel green light

A European Medicines Agency (EMA) panel on Friday recommended approving a potential blockbuster drug from Shire Plc to treat patients aged 12 and older with a rare hereditary disease that causes swelling in different parts of the body.

Shire's drug for rare swelling disorder wins European panel green light

Oct 19 A European Medicines Agency (EMA) panel on Friday recommended approving a potential blockbuster drug from Shire Plc to treat patients aged 12 and older with a rare hereditary disease that causes swelling in different parts of the body.

Takeda gets Japanese approval for $62 billion Shire purchase

Takeda Pharmaceutical Co Ltd said on Thursday Japan's Fair Trade Commission had approved its $62 billion (£47.3 billion) acquisition of Shire Plc , bringing the Japanese firm closer to sealing a deal that will make it a global top 10 drugmaker.

Takeda gets Japanese approval for $62 billion Shire purchase

Takeda Pharmaceutical Co Ltd said on Thursday Japan's Fair Trade Commission had approved its $62 billion acquisition of Shire Plc , bringing the Japanese firm closer to sealing a deal that will make it a global top 10 drugmaker.

UPDATE 1-Takeda gets Japanese approval for $62 bln Shire purchase

Oct 18 Takeda Pharmaceutical Co Ltd said on Thursday Japan's Fair Trade Commission had approved its $62 billion acquisition of Shire Plc, bringing the Japanese firm closer to sealing a deal that will make it a global top 10 drugmaker.

Takeda gets Japan's approval for $62 bln Shire purchase

Oct 18 Takeda Pharmaceutical Co Ltd said on Thursday Japan's Fair Trade Commission had approved its $62 billion acquisition of Shire Plc, bringing the Japanese firm closer to sealing a deal that will make it a global top 10 drugmaker.

Takeda's $62 billion Shire bid faces November 6 EU antitrust deadline

BRUSSELS EU antitrust regulators will decide by Nov. 6 whether to allow Japanese drugmaker Takeda Pharmaceutical's $62-billion takeover of London-listed Shire Plc , the European Commission said on Friday.

Takeda's $62 billion Shire bid faces Nov. 6 EU antitrust deadline

BRUSSELS EU antitrust regulators will decide by Nov. 6 whether to allow Japanese drugmaker Takeda Pharmaceutical's $62-billion (47.5 billion pounds) takeover of London-listed Shire Plc , the European Commission said on Friday.

Takeda's $62 bln Shire bid faces Nov. 6 EU antitrust deadline

BRUSSELS, Sept 28 EU antitrust regulators will decide by Nov. 6 whether to allow Japanese drugmaker Takeda Pharmaceutical's $62-billion takeover of London-listed Shire Plc, the European Commission said on Friday.

UPDATE 1-FTSE tracks Europe higher; Shire shines

MILAN, Sept 14 Britain's top share index tracked higher European markets on Friday with the mood buoyed by easing trade worries, while Shire rose after China cleared Takeda's plans to buy the drugmaker.

Select another date: